CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

NKG2D-based CAR-T in R/R AML and MDSПодробнее

Insights into NKG2D-targeting CAR-T cells in R/R AMLПодробнее

CAR T Cell Therapy in MDS/AMLПодробнее

NKG2D CAR-T cell therapy in AML/MDSПодробнее

Engineering multi-antigenic CAR T-cells for AMLПодробнее

Developing the next generation of CAR-T cellsПодробнее

NKG2D CARs for R/R AML and MDSПодробнее

NKG2D CAR T-cells & soluble NKG2D ligandsПодробнее

THINK trial: Phase I results for NKG2D CAR-T therapy in AMLПодробнее

David Sallman, MD, offers details regarding the clinical investigation of CYAD-01Подробнее

DARIC33 CAR T-cells in AMLПодробнее

Allogeneic CAR-NK cell therapy in R/R AML/MDSПодробнее

Advanced cell therapy based on the chimeric receptor NKG2D: the NK-T cell approachПодробнее

Deciphering CAR-T Cells: Exploring Functional Mechanisms to Drive Next Generation ImmunotherapyПодробнее

Future prospects for CAR-T cell therapy in AMLПодробнее

CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRCПодробнее

CAR-T - A Potential in Myeloid Cancers? - K CumminsПодробнее

CAR T Cell Therapy Explained (Animation) | City of HopeПодробнее

Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigenПодробнее